Disseminated intravascular coagulation in newborn

Summary

Disseminated intravascular coagulation in newborn (MONDO:0001242) is a disease. A subtype of disseminated intravascular coagulation — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	disseminated intravascular coagulation in newborn
Mondo ID	MONDO:0001242
DOID	DOID:11246
NCIT	C111856
SNOMED CT	34417008
UMLS	C0158992
MedGen	510687
GARD	0022907
Is cancer (heuristic)	no

Also known as: disseminated intravascular coagulation in newborn · neonatal disseminated intravascular coagulation

Disease family

This is a subtype of disseminated intravascular coagulation. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood coagulation disease › thrombophilia › disseminated intravascular coagulation › disseminated intravascular coagulation in newborn

Related subtypes (1): purpura fulminans

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.